Przejdź do zawartości
Merck

An update on the use of ophthalmic ketorolac tromethamine 0.4%.

Expert opinion on pharmacotherapy (2005-12-24)
Henry D Perry, Eric D Donnenfeld
ABSTRAKT

Ketorolac tromethamine 0.4% ophthalmic solution, a recent reformulation of the original ketorolac tromethamine 0.5% solution, is indicated for the reduction of ocular pain and burning/stinging following cataract and refractive surgery. Studies have demonstrated that ketorolac tromethamine 0.4% has equivalent efficacy to ketorolac tromethamine 0.5% in reducing postsurgical inflammation and controlling pain. Several studies have demonstrated that, as well as reducing pain and ocular inflammation, ketorolac tromethamine 0.4% effectively treats cystoid macular oedema, inhibits miosis and may prevent cystoid macular oedema when used both pre- and postoperatively. Ketorolac tromethamine 0.4% is a versatile agent and is effective when used as either monotherapy or as an adjunct therapy to steroids.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Ketorolac trometamol, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Ketorolac tris salt, ≥99%, crystalline
Supelco
Ketorolac Tromethamine, Pharmaceutical Secondary Standard; Certified Reference Material
Ketorolac trometamol for peak identification, European Pharmacopoeia (EP) Reference Standard